A J Kraker

1.0k citations

18 papers · 879 indexed · h-index 13

Hematology top 5%
- Chronic Myeloid Leukemia Treatments 4
Nutrition and Dietetics top 5%
- Trace Elements in Health 4
Genetics top 10%
- Chronic Lymphocytic Leukemia Research 4
Oncology top 10%
- Metal complexes synthesis and properties 3
Health, Toxicology and Mutagenesis top 10%
Organic Chemistry
- Synthesis and biological activity 5
- Click Chemistry and Applications 2
Molecular Biology
- PI3K/AKT/mTOR signaling in cancer 3
- Protein Kinase Regulation and GTPase Signaling 2

Co-authors: David H. Petering Charles Watson Moore C. Frank Shaw Richard Jove Jie Wu David W. Fry William A. Denny Jay F. Dorsey
Cited by: Hematology Nutrition and Dietetics Genetics
Journals: Journal of Medicinal Chemistry (3 papers)Leukemia (2 papers)Journal of Pharmacology and Experimental Therapeutics (1 paper)
Partner nations: United States New Zealand

In The Last Decade

A J Kraker

18 papers receiving 835 citations

Peers

Countries citing papers authored by A J Kraker

Since Specialization

Citations

This map shows the geographic impact of A J Kraker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A J Kraker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A J Kraker more than expected).

Fields of papers citing papers by A J Kraker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A J Kraker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A J Kraker. The network helps show where A J Kraker may publish in the future.

Co-authorship network

The 25 scholars most cited alongside A J Kraker, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with A J Kraker Line = papers co-authored together A J Kraker links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work
1	53 Pyrrolo[3,4-c]carbazole-1,3-dione inhibitors of the G2/M checkpoint kinase wee1 European Journal of Cancer Supplements ·Brian D. Palmer,R J Booth,William A. Denny,Kenneth E. Hook,A J Kraker,長沢里実,Daniel F. Ortwine,Jeff B. Smaill,C.J. Squire,Andrew M. Thompson	2004	1
2	Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors Leukemia ·M S Contreras,Rubén A. Haro-López,sana abujelban,Mei Huang,A J Kraker,Kapil N. Bhalla,Richard Jove,Jie Wu	2002	41
3	The pyrido[2,3-d]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. PubMed ·Jay F. Dorsey,Richard Jove,A J Kraker,Jie Wu	2000	130
4	Discovery of a novel abl tyrosine kinase inhibitor that selectively induces apoptosis of bcr-abl-positive leukemic cells Experimental Hematology ·Jay F. Dorsey,Richard Jove,A J Kraker,Jie Wu	2000	2
5	Therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth Leukemia ·Vera Roginskaya,Z. Wagner,Eva G. Caudell,Zijian Zhang,A J Kraker,А. Б. Золотарева	1999	79
6	1-Oxo-3-aryl-1H-indene-2-carboxylic acid derivatives as selective inhibitors of fibroblast growth factor receptor-1 tyrosine kinase Bioorganic & Medicinal Chemistry Letters ·Mark R. Barvian,Robert L. Panek,Gina H. Lu,A J Kraker,Aneesa M. Amar,Brian G. Hartl,James M. Hamby,H. D. Hollis Showalter	1997	11
7	Inhibition of Growth Factor-Mediated Tyrosine Phosphorylation in Vascular Smooth Muscle by PD 089828, a New Synthetic Protein Tyrosine Kinase Inhibitor Journal of Pharmacology and Experimental Therapeutics ·Garima Shivhare,Gina H. Lu,James M. Hamby,Brian L. Batley,A J Kraker,Robert L. Panek	1997	23
8	Tyrosine kinase inhibitors. 7. 7-amino-4-(phenylamino)- and 7-amino-4-[(phenylmethyl)amino]pyrido[4,3-d]pyrimidines: a new class of inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor Journal of Medicinal Chemistry ·Andrew M. Thompson,Alexander J. Bridges,David W. Fry,A J Kraker,William A. Denny	1995	127
9	Tyrosine kinase inhibitors. 2. Synthesis of 2,2'-dithiobis(1H-indole-3-alkanamides) and investigation of their inhibitory activity against epidermal growth factor receptor and pp60v-src protein tyrosine kinases Journal of Medicinal Chemistry ·Andrew M. Thompson,David W. Fry,A J Kraker,William A. Denny	1994	23
10	Tyrosine Kinase Inhibitors. 3. Structure-Activity Relationships for Inhibition of Protein Tyrosine Kinases by Nuclear-Substituted Derivatives of 2,2'-Dithiobis(1-methyl-N-phenyl-1H-indole-3-carboxamide) Journal of Medicinal Chemistry ·Gordon W. Rewcastle,Brian D. Palmer,Ellen M. Dobrusin,David W. Fry,A J Kraker,William A. Denny	1994	28
11	ChemInform Abstract: Tyrosine Kinase Inhibitors. Part 2. Synthesis of 2,2′‐Dithiobis(1H‐ indole‐3‐alkanamides) and Investigation of Their Inhibitory Activity Against Epidermal Growth Factor (EGF) Receptor and pp60v‐src Protein Tyrosine Kinases. ChemInform ·Andrew M. Thompson,David W. Fry,A J Kraker,William A. Denny	1994	3
12	Pentostatin: future directions. Pharmacological Reviews ·Wayne D. Klohs,A J Kraker	1992	20
13	Chemistry, cytotoxicity, and DNA-binding of bis-platinum complexes Journal of Inorganic Biochemistry ·A J Kraker,JL Prowting,Jens-Jørgen Mortensen,Nicholas P. Farrell,James D. Hoeschele,John D. Roberts	1989	7
14	Accumulation of cis-diamminedichloroplatinum(II) and platinum analogues by platinum-resistant murine leukemia cells in vitro. PubMed ·A J Kraker,Charles Watson Moore	1988	102
15	Zinc metabolism in Ehrlich cells: properties of a metallothionein-like zinc-binding protein. PubMed ·A J Kraker,Glenn R. Krakower,C. Frank Shaw,David H. Petering,Justine S. Garvey	1988	25
16	Binding of cis-dichlorodiammine platinum(II) to metallothionein in Ehrlich cells Biochemical and Biophysical Research Communications ·A J Kraker,James J. Schmidt,Susan Krezoski,David H. Petering	1985	51
17	Reaction of 3-ethoxy-2-oxobutyraldehyde bis(thiosemicarbazonato) Cu(II) with Ehrlich cells. Binding of copper to metallothionein and its relationship to zinc metabolism and cell proliferation. Journal of Biological Chemistry ·A J Kraker,Susan Krezoski,Jeffrey A. Schneider,Daniel T. Minkel,David H. Petering	1985	51
18	Ligand substitution reactions of metallothioneins with EDTA and apo-carbonic anhydrase. Proceedings of the National Academy of Sciences ·Faiz Fikri Alfahmi,A J Kraker,C. Frank Shaw,David H. Petering	1980	155

About A J Kraker

A J Kraker is a scholar working on Hematology, Genetics and Oncology, having authored 18 papers that have together received 879 indexed citations. Recurring topics across this work include Synthesis and biological activity (5 papers), Chronic Lymphocytic Leukemia Research (4 papers), Trace Elements in Health (4 papers), Chronic Myeloid Leukemia Treatments (4 papers), Metal complexes synthesis and properties (3 papers), PI3K/AKT/mTOR signaling in cancer (3 papers), Click Chemistry and Applications (2 papers) and Protein Kinase Regulation and GTPase Signaling (2 papers). The work is most often cited by research in Hematology (245 citations), Nutrition and Dietetics (224 citations) and Genetics (135 citations). A J Kraker has collaborated with scholars based in United States and New Zealand. Frequent co-authors include David H. Petering, Charles Watson Moore, C. Frank Shaw, Richard Jove, Jie Wu, David W. Fry, William A. Denny, Jay F. Dorsey, Andrew M. Thompson and Alexander J. Bridges. Their work appears in journals such as Journal of Medicinal Chemistry, Leukemia, Journal of Pharmacology and Experimental Therapeutics, Journal of Biological Chemistry and Bioorganic & Medicinal Chemistry Letters.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact